

Drug Monograph

Drug/Drug **Asmanex™ HFA (mometasone furoate) aerosol /Inhaled**
 Class: **Corticosteroid**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Asmanex™ HFA is available as a 100 mcg and 200 mcg pressurized aluminum canister that contains 120 metered actuations of 100 mcg and 200 mcg of mometasone furoate respectively.	
Manufacturer:	Manufactured by: 3M Health Care Ltd., Loughborough, United Kingdom Manufactured for: Merck & Co., Inc., Whitehouse Station, NJ 08889	
Indications:	Asmanex™ HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.	
Costs:	\$156 per 100 mcg canister and \$183.43 per 200 mcg canister of Asmanex™ HFA. Wholesale Acquisition Cost	
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Non-Preferred Agent
	<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Under Solicitation

Prepared By: Luke Boehmer Pharm.D.
 Date: March 5, 2015